John William Jacobs
Directeur Technique/Scientifique/R&D chez Phage Biotechnology Corp.
Profil
John William Jacobs is currently the Director at Cardio Phage International, Inc. and the Chief Scientific Officer & Vice President at Phage Biotechnology Corp.
He previously held positions as Director at National Penn Bancshares, Inc., Director-Basic Research at Hitachi Chemical Research Center, Inc., Assistant Professor at the University of Texas Health Center, and Head-Biological Chemistry Department at Merck Sharp & Dohme Research Laboratories.
From 2011 to 2014, he was the Director, VP, Chief Operating & Scientific Officer at Venturis Therapeutics, Inc. He received his doctorate from Washington University in St. Louis in 1978 and his undergraduate degree from Davidson College.
Postes actifs de John William Jacobs
| Sociétés | Poste | Début |
|---|---|---|
Phage Biotechnology Corp.
 Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Directeur Technique/Scientifique/R&D | 01/04/2000 |
| Cardio Phage International, Inc. | Directeur/Membre du Conseil | 01/01/1998 |
Anciens postes connus de John William Jacobs
| Sociétés | Poste | Fin |
|---|---|---|
Venturis Therapeutics, Inc.
 Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Directeur Technique/Scientifique/R&D | 16/09/2014 |
| Hitachi Chemical Research Center, Inc. | Directeur Technique/Scientifique/R&D | 01/04/2000 |
| University of Texas Health Center | Corporate Officer/Principal | - |
| Merck Sharp & Dohme Research Laboratories | Corporate Officer/Principal | - |
| NATIONAL PENN BANCSHARES | Directeur/Membre du Conseil | - |
Formation de John William Jacobs
| Davidson College | Undergraduate Degree |
| Washington University in St. Louis | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
National Penn Bancshares, Inc.
 National Penn Bancshares, Inc. Major BanksFinance National Penn Bancshares, Inc. operates as a bank holding company, which provides financial and banking services through its subsidiary, National Penn Bank. It operates through the Community Banking and Other segment. The Community Banking segment provides commercial banking and consumer banking services, including deposit accounts, demand, NOW, money market, other checking and savings accounts and certificates of deposits. The Other segment includes wealth management where commercial and consumer banking operations, including mortgage lending services are provided. Its consumer loan products include installment loans, home equity loans, residential mortgage loans, multi-family loans, educational loans and credit cards. The company was founded in January 1982 and is headquartered in Allentown, PA. | Finance |
Venturis Therapeutics, Inc.
Venturis Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Venturis Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the developing protein drug candidates to address diseases such as diabetic wounds, severe coronary heart disease and peripheral artery disease. The company develops injectable and topical formulations of its active pharmacological ingredient to facilitate the growth of new blood vessels in the heart, tissues and organs. It focuses on developing protein drug candidates to be used in the treatment of cardiovascular disease. CardioVascular BioTherapeutics was founded by Daniel C. Montano, Thomas J. Stegmann and Grant Gordon in March 1998 and is headquartered in Dallas, TX. | Commercial Services |
Phage Biotechnology Corp.
Phage Biotechnology Corp. Pharmaceuticals: MajorHealth Technology Phage Biotechnology Corp. manufactures protein pharmaceuticals including pegylated human growth hormone, pegylated G-CSF, pegylated interferon alpha, beta interferon, and single-chain antibodies. It also develops biopharmaceuticals whose patents expire. The company was founded in 1998 and is headquartered in Las Vegas, NV. | Health Technology |
| Cardio Phage International, Inc. | |
| Hitachi Chemical Research Center, Inc. | |
| Merck Sharp & Dohme Research Laboratories |
